scholarly journals Long non-coding RNA TP73-AS1 is a potential immune related prognostic biomarker for glioma

Aging ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 5638-5649
Author(s):  
Bo Zhang ◽  
Qinglin Li ◽  
Bin Wu ◽  
Shuyuan Zhang ◽  
Liwen Li ◽  
...  
Keyword(s):  
Prognostic Biomarker ◽  
Non Coding Rna ◽  
Long Non Coding Rna

scholarly journals The long non-coding RNA ADAMTS9-AS2 was identified as a potential prognostic biomarker in triple-negative breast cancer

2020 ◽  
Vol 6 (3) ◽  
pp. 16215-16226
Author(s):  
Daniel Rodrigues Bastos ◽  
Jean Michel Rocha Sampaio Leite ◽  
Mércia Patrícia Ferreira Conceição ◽  
Cesar Augusto Sam Tiago Vilanova-Costa ◽  
Antonio Márcio Teodoro Cordeiro Silva ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Prognostic Biomarker ◽  
Non Coding Rna ◽  
Long Non Coding Rna

Long non-coding RNA CRNDE as a potential prognostic biomarker in solid tumors: A meta-analysis

2018 ◽  
Vol 481 ◽  
pp. 99-107 ◽  
Author(s):  
Chaojie Liang ◽  
Bing Zhang ◽  
Hua Ge ◽  
Yingchen Xu ◽  
Guangming Li ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Prognostic Biomarker ◽  
Meta Analysis ◽  
Non Coding Rna ◽  
Long Non Coding Rna

The prognostic value of long non-coding RNA PlncRNA-1 in patients with cancers: a systematic review and meta-analysis

2020 ◽  
Author(s):  
Lijun Lei ◽  
Lianbing Sheng ◽  
Lingyuan Wu ◽  
Jiaojing Liu ◽  
Bin Wei ◽  
...  
Keyword(s):  
Web Of Science ◽  
Prognostic Biomarker ◽  
Meta Analysis ◽  
Database Search ◽  
Clinical Prognosis ◽  
Non Coding Rna ◽  
Increased Risk ◽  
Cancer Types ◽  
The Relationship ◽  
Long Non Coding Rna

Abstract Background We performed this meta-analysis to elucidate whether the expression of PlncRNA-1 might serve as an effective prognostic marker for various cancers. Methods We conducted a database search of PubMed, ScienceDirect, Embase, Web of Science and CNKI database (up to Oct 31, 2019). The pooled hazard ratio (HR), odds ratio (OR) and 95% confidence interval (CI) were used to estimate the strength of the relationship between PlncRNA-1 expression and the clinical prognosis of cancer patients. Results The results showed that elevated PlncRNA-1 expression predicted a poor OS with pooled HRs of 1.43 (95% CI: 1.25-1.63, I 2 =63.1%, P=0.004). Likewise, we found that advanced tumour stages were associated with upregulated PlncRNA-1 expression in various cancer types (III–IV vs I–II: OR=2.79, 95% CI: 1.76-4.41, I 2 =0%, P=0.822),patients with high PlncRNA-1 expression might have an increased risk of large tumours (OR=2.03, 95% CI: 1.31-3.14, I 2 =67.1%, P=0.028). Conclusions PlncRNA-1 might be used as a prognostic biomarker and as a tool for the early detection of various tumours.

scholarly journals An eight-long non-coding RNA signature as a candidate prognostic biomarker for lung cancer

2016 ◽  
Vol 36 (1) ◽  
pp. 215-222 ◽  
Author(s):  
ZHENBO TU ◽  
DU HE ◽  
XINZHOU DENG ◽  
MENG XIONG ◽  
XIAOXING HUANG ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Prognostic Biomarker ◽  
Non Coding Rna ◽  
Long Non Coding Rna ◽  
Rna Signature

scholarly journals Expression profiling of long non-coding RNA identifies linc-RoR as a prognostic biomarker in oral cancer

Tumor Biology ◽  
2017 ◽  
Vol 39 (4) ◽  
pp. 101042831769836 ◽  
Author(s):  
Ganesan Arunkumar ◽  
Arunagiri Kuha Deva Magendhra Rao ◽  
Mayakannan Manikandan ◽  
Kanagaraj Arun ◽  
Vilvanathan Vinothkumar ◽  
...  
Keyword(s):  
Oral Cancer ◽  
Expression Profiling ◽  
Prognostic Biomarker ◽  
Non Coding Rna ◽  
Long Non Coding Rna

scholarly journals The Role of lncRNA PCAT6 in Cancers

2021 ◽  
Vol 11 ◽  
Author(s):  
Siying Wang ◽  
Zhenyao Chen ◽  
Jingyao Gu ◽  
Xin Chen ◽  
Zhaoxia Wang
Keyword(s):  
Breast Cancer ◽  
Prognostic Biomarker ◽  
Malignant Tumors ◽  
Vital Role ◽  
Cancer Breast ◽  
Non Coding Rna ◽  
Different Types ◽  
Cancer Côlon ◽  
Long Non Coding Rna

Long non-coding RNA (lncRNA) PCAT6 is a member of the Prostate Cancer Associated Transcripts family of molecules. In this review, we focus on the latest studies involving PCAT6 in the diagnosis, treatment, and prognosis of malignant tumors of the digestive, respiratory, urinary, reproductive, motion, and nervous systems. PCAT6 was found to be highly expressed in gastric cancer, colon cancer, hepatocellular carcinoma, lung cancer, bladder cancer, ovarian cancer, breast cancer, cervical cancer, osteosarcoma, glioblastoma, and other tumors. PCAT6 can promote the development and progression of different types of malignant tumors through various mechanisms. Overall, these findings suggest that PCAT6 may play an increasingly vital role in the clinical assessment of these malignant tumors. It can function as an oncogene and may be used as a potential new prognostic biomarker of these tumors.

Sign in / Sign up

Export Citation Format

Share Document